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PsychostimulantsAbstract Purpose: Cognitive alterations are reported in breast cancer patients receiving che-
motherapy. This has adverse effects on patients’ quality of life and function. This systematic
review investigates the effectiveness of pharmacologic and non-pharmacologic interventions
to manage cognitive alterations associated with breast cancer treatment.
Methods: Medline via EBSCO host, CINAHL and Cochrane CENTRAL were searched for
the period January 1999–May 2014 for prospective randomised controlled trials related to
the management of chemotherapy-associated cognitive alterations. Included studies
investigated the management of chemotherapy-associated cognitive alterations and used
438 R.J. Chan et al. / European Journal of Cancer 51 (2015) 437–450subjective or objective measures in patients with breast cancer during or after chemotherapy.
Two authors independently extracted data and assessed the risk of bias.
Results: Thirteen studies involving 1138 participants were included. Overall, the risk of bias
for the 13 studies was either high (n = 11) or unclear (n = 2). Pharmacologic interventions
included psychostimulants (n = 4), epoetin alfa (n = 1) and Ginkgo biloba (n = 1). Non-phar-
macologic interventions were cognitive training (n = 5) and physical activity (n = 2). Pharma-
cologic agents were ineffective except for self-reported cognitive function in an epoetin alfa
study. Cognitive training interventions demonstrated beneﬁts in self-reported cognitive func-
tion, memory, verbal function and language and orientation/attention. Physical activity inter-
ventions were effective in improving executive function and self-reported concentration.
Conclusion: Current evidence does not favour the pharmacologic management of cognitive
alterations associated with breast cancer treatment. Cognitive training and physical activity
interventions appear promising, but additional studies are required to establish their efﬁcacy.
Further research is needed to overcome methodological shortfalls such as heterogeneity in
participant characteristics and non-standardised neuropsychological outcome measures.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Alterations in cognitive function are often observed
in patients receiving chemotherapy, particularly those
treated for breast cancer [1]. These changes can comprise
poor word or name recall, diﬃculty in staying focused,
diminished ability to learn new things and a decreased
ability to multitask [2]. Other alterations in executive
function, information processing speed, language,
motor function and spatial skills are documented.
Depending on the nature of the malignancy and the
treatment regimen, the time of onset, severity and dura-
tion of these changes are highly variable [3], as are its
aﬀective, functional and psychosocial outcomes [4].
Depending on the type of cancer investigated, esti-
mates of the prevalence of cancer treatment-related
alterations in cognitive function range from 16% to
75% during treatment [5], although they can endure
beyond treatment. Supported by ﬁndings from neuro-
psychological tests, reports indicate that individuals
can experience longer-term cognitive changes for as long
as 21 years after chemotherapy for breast cancer [6]. In
addition, imaging research has reported a correlation
between deﬁcits in cognitive function and white matter
changes in the brain [7].
A number of systematic reviews and meta-analyses
have investigated the prevalence of cognitive alteration
and its association with treatment in cancer patients
[2,8,9]. One systematic review [10] and one non-system-
atic narrative review, which discussed unpublished and
ongoing studies [11], focused on interventions to
enhance cognitive function. Both reviews, however,
are limited in that they included non-randomised con-
trolled trials. Furthermore, Hines et al. limited their
studies to cognitive behavioural therapy (CBT), which
does not encompass the full range of interventions
available [10]. In summary, a high quality, comprehen-
sive systematic review of interventions for managingchemotherapy-associated cognitive alterations is
lacking.
This clinical problem has signiﬁcant adverse eﬀects
on the post-treatment quality of life and function of
patients with cancer; hence, interventions to prevent or
manage it are warranted. Over the next decade, the
number of individuals living with a cancer diagnosis is
projected to increase by 31%, with a high proportion
being patients with breast cancer [12]. Treatment-associ-
ated adverse eﬀects in this growing population have sig-
niﬁcant public health implications if they are not well
managed. In this paper, we systematically review the
eﬀectiveness of pharmacologic and non-pharmacologic
interventions to manage alterations of cognitive func-
tion associated with breast cancer treatment.
2. Method
This systematic review adhered to the PRISMA state-
ment [13] for reporting systematic reviews.
2.1. Search strategy
A medical librarian (JD) searched Medline via
EBSCOhost, CINAHL and Cochrane CENTRAL for
studies published between January 1999 and May
2014. The key search terms were chemotherapy, anti-
neoplastic agents, chemoradiotherapy, cancer, neo-
plasms, randomised controlled trial, cognitive
impairment, cognitive dysfunction, cognitive disorder,
cognitive loss, cognitive deﬁcit and memory disorder.
The search was limited to prospective randomised con-
trolled trials (RCTs) published in English that investi-
gated the management of chemotherapy-associated
cognitive alterations (as primary or secondary out-
comes). Further manual searches of the reference lists
of the relevant studies and reviews were undertaken by
authors AC, RC and AM.
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Three authors (RC, AM and AC) pre-screened all the
search results (titles and abstracts) and after consensus
was reached for possible inclusion, the full text of all
selected papers was assessed. Studies were included if
they were prospective RCTs; reported pharmacologic
or non-pharmacologic interventions for cognitive altera-
tions in breast cancer patients during or after chemo-
therapy or multimodal therapy including
chemotherapy; and used subjective or objective mea-
sures of cognitive function. Investigations of patients
with secondary brain metastases and studies with less
than 50% of breast cancer patients in the sample or with
patients receiving radiation monotherapy were
excluded. Unpublished reports, letters to the editor, ret-
rospective chart reviews and non-RCTs were also
excluded.2.3. Data extraction and rating of articles for risk of bias
Two authors (RC, AM or AC) independently
extracted the data using a pre-designed, piloted form.
Studies were independently rated according to the Coch-
rane Collaboration’s risk of bias (ROB) criteria for a
high, low or unclear ROB with respect to random
sequence generation, allocation concealment, blinding,
incomplete outcome data, selective outcome reporting
and other sources of bias [14]. An ‘unclear’ ROB was
assigned to a study if the risk was unclear in one or more
domains, with no domain rated as high risk. A ‘high’
ROB was assigned to a study if the risk was high in
one or more domains. A ‘low’ ROB was assigned to a
study rated as low risk in all domains [15]. Diﬀerences
in ratings were settled by discussion or by a third person
if consensus was not achieved by the two primary
reviewers.
Studies that compared an intervention to usual care,
placebo or another intervention and that presented ade-
quate data for the calculation of eﬀect size were evalu-
ated. To determine the eﬀects of the interventions in
any of the included studies, eﬀect sizes (mean diﬀerence
[MD] or relative risk with a 95% conﬁdence interval
[CI]) were calculated using Review Manager 5 [14].
We classiﬁed outcome assessments of <3 months,
3–6 months and P6 months as short-, medium- and
long-term time points, respectively. If more than one
measurement was reported within the deﬁned period,
the latest assessment was extracted. When published
articles presented insuﬃcient data to calculate the eﬀect
sizes, the authors were contacted for the required infor-
mation. Although some studies reported statistical anal-
yses for within-group changes from the baseline,
between-group diﬀerences were analysed to determine
the eﬀects of the interventions (positive, negative or
inconclusive). Data elicited from screening measures(e.g. Mini Mental Status Exam or High Sensitivity Cog-
nitive Screen) were not extracted or analysed. Objective
outcome data were classiﬁed into the seven pre-deﬁned
domains of cognitive function recommended by Lezek
et al. [16] and Hodgson et al. [17].
The interventions and outcome measurements
reported in these studies were heterogeneous. Therefore,
meta-analysis was not undertaken.3. Results
Screening of 555 citations identiﬁed a total of 29
potentially relevant papers, the full texts of which were
retrieved. Thirteen of the 29 studies were excluded as
the majority of the included participants did not have
breast cancer [18–30]; two studies did not include cogni-
tive function measurement [31,32]; and one study was
not an RCT [33]. Thirteen studies met the inclusion cri-
teria for quantitative and qualitative analyses. A ﬂow-
chart detailing the identiﬁcation of studies is provided
in Fig. 1.
Thirteen studies with a total of 1138 participants were
included in this review [34–46]. Eleven were undertaken
in North America, one in Japan and the other in France.
Six studies evaluated pharmacologic interventions (psy-
chostimulants, n = 4; erythropoietin stimulating agent,
n = 1, Gingko biloba, n = 1). Seven studies investigated
non-pharmacologic interventions, ﬁve of which involved
cognitive training through forms of cognitive behav-
ioural (n = 4) or mindfulness therapy (n = 1) and two
of which explored physical activity. The characteristics
of the included studies, the age of participants, treat-
ments received, time since chemotherapy, sample sizes,
assessment outcomes and time points for assessments
are listed in Table 1.
Ten studies provided speciﬁc information on how the
random sequence was generated. One provided suﬃcient
information on allocation concealment [38]. The blind-
ing of participants, personnel and outcome assessments
was achieved in the six pharmacologic placebo trials but
was not possible in the seven non-pharmacologic inter-
ventions. The risk of incomplete data outcome reporting
bias was detected in six trials [34–37,44,45], which did
not provide reasons for participant dropout, or did
not undertake intention-to-treat analyses. Three studies
[35,37,38] had selective outcome reporting bias, as they
did not report the data on all outcomes measured. Over-
all, the ROB for the 13 studies was either high [34–
40,43–46] (n = 11) or unclear [41,42] (n = 2) (Table 2).3.1. Pharmacologic interventions
3.1.1. Psychostimulants
Psychostimulants including d-methylphenidate
(d-MPH) (n = 2), methylphenidate (n = 1) and modaﬁ-
nil (n = 1) were evaluated. Two studies [41,42] evaluated
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Fig. 1. PRISMA ﬂow diagram.
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et al.’s study [41], patients were prescribed on 5 mg
d-MPH twice daily with doses titrated weekly to a max-
imum of 50 mg/day over 8 weeks. In the other d-MPH
study, conducted by Mar Fan et al. [42] patients who
demonstrated compliance through a placebo run-in
phase were randomised to d-MPH 5 mg twice daily or
to matched placebo. Doses were titrated to a maximum
of 10 mg twice daily until the end of the ﬁnal cycle of
chemotherapy. In another cross-over study [37], breast
cancer patients were randomised to methylphenidate
18 mg/day for 2 weeks followed by placebo for 2 weeks
or vice versa. Modaﬁnil was trialed in a study involving
two phases [40]. In the ﬁrst phase, all patients received
modaﬁnil 100 mg once daily for 3 days and 200 mg once
daily during an open-label period of 4 weeks. In the sub-
sequent phase, patients who achieved a positive response
in terms of attention and memory in the ﬁrst phase were
randomised to an additional 4 weeks of modaﬁnil
200 mg/day or placebo. In the assessment of short-term
and medium-term cognitive measures between thepsychostimulants and controls, there was no statistically
signiﬁcant diﬀerence in cognitive measures in any of the
studies (Table 3).
3.1.2. Epoetin alfa (EPO)
O’Shaughnessy et al. [45] evaluated whether epoetin
alfa (EPO) could enhance cognitive and execution func-
tion in patients with breast cancer receiving adjuvant
chemotherapy. Patients were randomised to receive
40,000 U of EPO subcutaneously weekly or a compara-
ble volume of placebo during adjuvant or neoadjuvant
chemotherapy over a maximum of 12 weeks. EPO doses
were titrated according to haemoglobin levels. An
improvement in self-perceived cognitive function
(EXIT-25) was noted in patients receiving EPO com-
pared to a placebo (MD = 1.60 [95% CI, 2.81 to
0.39]).
3.1.3. Gingko biloba
Barton et al. [34] investigated whether Ginkgo biloba
could prevent cognitive impairment in breast cancer
Table 1
Characteristics of included studies (n = 13).
Study Participants Prior treatments Time since
chemotherapy
Comparisons Domains examined Assessed time
point
Barton (2013) [34]
USA
Breast CA:
Both arms: 100%
Age:
I :P50 years: 50%
C: P50 years: 50%
I: AC: 33%;
AC and taxane: 52%
Others: 15%
Tam planned: 51%
C: AC: 36%;
AC and taxane: 52%
Others: 12%
Tam planned: 54%
During chemo Ginkgo biloba 60 mg versus
placebo twice daily (started at the
second cycle of chemo and ceased at
1 month after completion of chemo)
I: n = 107
C: n = 103
Orientation and attention, self-
reported cognitive function
Short-term,
medium-term,
long-term
Culos-Reed (2006)
[35]
Canada
Breast CA:
Both arms: 100%
Age:
Both arms: 51.2 (10.3)
Both arms: Chemo: percentage
not stated
>3 months post
chemo
7-week yoga programme versus
control
I: n = 10
C: n = 10
Self-reported cognitive function Short-term
Dolbeault (2009)
[36]
France
Breast CA:
Both arms: 100%
Age:
I: 54.5 (9.3)
C: 51.6 (9.6)
I: Chemo: 45.1%
C: Chemo: 61.4%
Not stated A CBT-based psycho-educational
group intervention (8 weekly 2-h
sessions) versus control (usual care)
I: n = 102
C: n = 101
Self-reported cognitive function Short-term
Escalante (2014) [37]
USA
Breast CA:
Both arms: 100%
Age:
Both arms:
Median 57 (Range: 32–
79)
Both groups:
Chemo: 100%
Either
undergoing or
completed
treatment in the
previous
12 months
Methylphenidate (18 mg daily)
versus placebo for 14 days
n = 42 (cross-over design)
Orientation and attention Short-term
Ferguson (2012) [38]
USA
Breast CA:
Both arms: 100%
Age:
I: 51.2 (7.3)
C: 49.4 (5.1)
I: Received AC/FAC
C: Received AC/FAC
>18 months
post chemo
8-week Memory and Attention
Adaptive Training (MAAT) versus
waitlist control
I: n = 19
C: n = 21
Orientation and attention,
executive function and motor
function, memory, self-reported
cognitive function
Short-term
Kesler (2013) [39]
USA
Breast CA:
Both arms: 100%
Age:
I: 55.0 (7)
C: 56.0 (6)
I: 100% chemo
70% RT
60% HT
C: 100% chemo
63% RT
63% HT
Mean (SD): 6.0
(3) months
Online computerised training
programme (5 exercises 4 times
weekly for 12 weeks) versus usual
care
I: n = 21
C: n = 21
Orientation and attention,
executing functioning and motor
function, verbal function and
language skills, memory, self-
reported cognitive function
Short-term
Kohli (2012) [40]
USA
Breast CA:
Both arms: 100%
Age:
I: 54.0 (10.3)
C: 56.35 (11.4)
I: 100% chemo, 82% RT
C: 100% chemo, 85% RT
>30 days post
chemo
Modaﬁnil 200 mg daily versus
placebo for 4 weeks
I: n = 34
C: n = 34
Orientation and attention, memory Short-term
(continued on next page)
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Table 1 (continued)
Study Participants Prior treatments Time since
chemotherapy
Comparisons Domains examined Assessed time
point
Lower (2009) [41]
USA
Breast CA:
I: 78%
C: 73%
Age:
I: 52.5 (10.2)
C: 53.2 (8.4)
I: 100% chemo
C: 100% chemo
Mean (SD):
115.3 (106.5)
weeks
D-methylphenidate versus placebo
for 8 weeks; dose modiﬁcations
were allowed; max 50 mg/day
I: n = 76
C: n = 78
Orientation and attention Short-term
Mar Fan (2008) [42]
Canada
Breast CA:
Both arms: 100%
Age:
I: Median = 50,
Range = 36–72
C: Median = 51,
Range = 37–74
Both arms:
100% Chemo
Both arms:
AC: 100%
Cy: 96.5%
5FU: 33.3%
Taxane: 31.6%
I: Median
(range): 84 (23–
141) days post
chemo C:
Median (range):
85 (26–131) days
post chemo
D-methylphenidate (titration: 5to
10 mg twice daily) versus placebo
until ﬁnal cycle of chemo
I: n = 28
C: n = 29
Memory Short-term
Miki (2014) [43]
Japan
Breast CA:
I: 55.3%
C: 55.0%
Age:
I: 72.97 (4.57)
C: 75.45 (6.57)
I: 81.6% Surgery
23.7% Chemo
68.4% HT
68.4% RT
C: 72.5% Surgery
27.5% Chemo
80.0% HT
4.00% RT
Not stated 4-week Speed-feedback therapy
with a bicycle ergometer versus
usual care
I: n = 38
C: n = 40
Executing function and motor
function
Short-term
Milbury (2014) [44]
USA
Breast CA:
Both arms: 100%
Age:
I: 53.0 (6.6)
C: 54.1 (8.6)
I: 100% chemo
73.9% RT 87% Surgery
C: 100% chemo
79.2% RT
100% Surgery
6–60 months
post chemo
Tibetan sound meditation (2x
weekly sessions for 6 weeks) versus
waitlist control
I: n = 18
C: n = 24
Orientation and attention,
memory, verbal functions and
language skills, self-reported
cognitive function
Short-term
O’Shaughnessy
(2005) [45]
USA
Breast CA:
Both arms: 100%
Age:
I: 53.3 (9.7)
C: 54.3 (12)
Both arms:
100% chemo
Both arms:
Doxorubicin/eprubicin:100%
Cy: 96.8%
5-FU: 11.7%
Taxane: 24.5%
Undergoing
chemo
40,000U epoetin alfa subcutaneous
weekly versus placebo (started on
D1 of cycle 1 of 4 cycles of chemo,
and continued for a maximum of
12 weeks)
I: n = 47
C: n = 47
Executive function and motor
function, self-reported cognitive
function
Short-term,
long-term
Von Ah (2012) [46]
USA
Breast CA:
All three arms: 100%
Age:
I1: 55.19 (7.58)
I2: 56.93 (7.83)
C: 57.21 (9.8)
All three arms: 100% chemo 1 year post
chemo
Memory training (Advanced
Cognitive Training for Independent
and Vital Elderly (ACTIVE)
programme (10 sessions for
6–8 weeks) versus speed of
processing training (Posit Science)
(10 sessions for 6–8 weeks) versus
waitlist group
I1: n = 29
I2: n = 30
C: n = 29
Memory, self-reported cognitive
function
Short-term
Abbreviations: 5-FU: 5-Fluorouracil; AC: Anthracycline and cyclophosphamide; C: Control; CBT: Cognitive behavioural therapy; Cy: Cyclophosphamide; Chemo: Chemotherapy; FAC: 5-Fluo-
rouracil, anthracycline and cyclophosphamide; HT: Hormonal therapy, I: Intervention, RT: Radiation therapy. Tam: Tamoxifen. Measurement time points: short term: less than 3 months; medium
term: 3–6 months; long term: beyond 6 months.
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Table 2
Risk of bias (ROB) table for included studies (n = 13).
Study Sequence
generation
Allocation
concealment
Blinding of
participants
and personnel
Blinding of
outcome
assessment
Incomplete
outcome data
Selective
outcome
reporting
Other
sources
of bias
Level
of risk
Barton (2013) [34] + 0 + +  + + H
Culos-Reed (2006) [35] 0 0 0    + H
Dolbeault (2009) [36] + 0    + + H
Escalante (2014) [37] 0 0 + + 0  + H
Ferguson (2012) [38] + + + + +  + H
Kesler (2013) [39] + 0  0 + + + H
Kohli (2012) [40] + 0 + + + +  H
Lower (2009) [41] + 0 + + + + + U
Mar Fan (2008) [42] 0 0 + + + + + U
Miki (2014) [43] + 0  + + + + H
Milbury (2014) [44] + 0  0 0 + + H
O’Shaughnessy (2005) [45] + 0 + +  + + H
Von Ah (2012) [46] + 0   + + + H
0 represents an unclear ROB;  represents a high ROB and + represents a low ROB. Abbreviations: H, high ROB () for one or more domains; L,
low ROB (+) for all domains; U, unclear ROB for one or more domains.
R.J. Chan et al. / European Journal of Cancer 51 (2015) 437–450 443patients receiving adjuvant chemotherapy. Patients were
randomised to receive Ginkgo biloba 60 mg twice daily
or a placebo. The intervention commenced at the second
cycle of chemotherapy and continued until 1 month
after the completion of chemotherapy. The authors con-
cluded that there were no signiﬁcant diﬀerences in either
subjective or objective cognitive measures between the
two groups.
3.1.4. Toxicities of pharmacologic interventions
Five of the six studies [34,37,41,42,45] evaluating
pharmacologic interventions reported adverse events
associated with the interventions and the placebo. The
adverse events were generally mild, with few Common
Terminology Criteria for Adverse Events (CTCAE)
Grade 3 or 4 toxicities were reported. In the two studies
investigating d-MPH versus a placebo [41,42], higher
incidences of dry mouth, nausea, dizziness, insomnia,
anxiety and nervousness were reported among patients
receiving d-MPH compared to the placebo. Similar ﬁnd-
ings were found in the methylphenidate study [37]. In
the EPO study, O’Shaughnessy et al. [45] reported a
fatal cerebrovascular accident in one patient in the
EPO group. Gingko biloba was generally well tolerated
compared to the placebo, with the exception of nausea,
which was worse in the placebo group [34].
3.2. Non-pharmacologic interventions
3.2.1. Cognitive training
In their three-arm study, Von Ah et al. [46] delivered
memory training in one arm and speed processing train-
ing in the other. Memory training entailed the teaching
of strategies to remember word lists, sequences and text
material and learning how to apply the principles of
meaningfulness, organisation, visualisation and associa-
tion to these activities. Strategies focused on multiple
mnemonic techniques. The intervention comprised 10sessions, the ﬁrst ﬁve comprising strategy instruction
and practice, and the last ﬁve comprising practical exer-
cises. This study reported a signiﬁcant improvement in
memory using objective neuropsychological testing
compared to the control group, measured using compos-
ite scores for both immediate memory recall
(MD = 0.31, [95% CI, 0.04–0.58]) and long term delayed
memory (MD = 0.46, [95% CI, 0.12–0.80]). When self-
perceived cognition for this intervention was measured
with the Functional Assessment of Cancer Therapy-
Cognitive Function (FACT-Cog), the results demon-
strated a statistically signiﬁcant improvement in the
intervention group compared to the control group
(MD = 9.85 [95% CI, 1.67–18.03]) (Table 4). The other
arm of the study involved speed processing training,
which aimed to systematically reduce stimulus duration
during a series of progressively more diﬃcult computer-
ised information processing tasks. Exercises comprised
time-order judgment, discrimination, spatial match, for-
ward span, instruction following and narrative memory
tasks. Although the speed processing training did not
target speciﬁcally at memory improvement, the training
yielded positive improvement in memory, measured
using composite scores for both immediate memory
recall (MD = 0.43, [95% CI, 0.16–0.70]) and long term
delayed memory (MD = 0.47, [95% CI, 0.13–0.81]).
Kesler et al. [39] targeted executive function, which in
their study encompassed working memory, cognitive
ﬂexibility, multitasking, planning and attention. The
intervention comprised an online computerised training
programme undertaken in the participants’ homes. It
spanned 48 sessions of 20–30 min each over 6 weeks,
with each session comprising combinations of 13 diﬀer-
ent exercises to enhance core executive function. Each
participant logged in four times per week to complete
ﬁve separate exercises. Exercises involved computerised
visual stimuli that required a motor response such as a
mouse click plus immediate feedback and reinforcement.
Table 3
Pharmacologic interventions and outcomes (n = 6).
Categories Intervention Tool Domains
examined
Assessment
time point
Eﬀect size Conclusion
Psychostimulants Dexmethylphenidate
[41]
Modiﬁed Swanson, Nelson and
Pelham Attention Deﬁcit/
Hyperactivity Scale (SNAP)
Orientation
and attention
Short-term MD = 0.30
(95% CI, 2.19
to 2.79)
Negative
Dexmethylphenidate
[42]
Hopkins Verbal Learning Test-
Revised (HVLT-R)
Memory Medium-
term
RR = 1.20 (95%
CI, 0.72–2.00)
Negative
Methylphenidate [37] Digit Span Orientation
and attention
Short-term Data not
reported
Inconclusive
Modaﬁnil [40] Cognitive Drug Research
Computerised Assessment
System# (Power of Attention)
Orientation
and attention
Short-term MD = 27.64
(95% CI, 89.66
to 34.38)
Negative
Cognitive Drug Research
Computerised Assessment
System# (Continuity of Attention)
Orientation
and attention
Short-term MD = 0.65
(95% CI, 0.65
to 1.95)
Negative
Cognitive Drug Research
Computerised Assessment
System# (Episodic Secondary
Memory)
Memory Short-term MD = 4.52
(95% CI, 29.84
to 20.80)
Negative
Cognitive Drug Research
Computerised Assessment
System# (Working Memory)
Orientation
and attention
Short-term MD = 0.12
(95% CI, 0.06
to 0.30)
Negative
Cognitive Drug Research
Computerised Assessment
System# (Speed of Memory)
Orientation
and attention
Short-term MD = 103.46
(95% CI,
567.03 to
360.10)
Negative
Erythropoietic
stimulating
agent
Epoetin alfa [45] Executive Clock Drawing Task 1
(CLOX1)
Executive
function and
motor
function
Short-term MD = 0.10
(95% CI, 0.93
to 1.13)
Negative
Executive Clock Drawing Task 1
(CLOX1)
Executive
function and
motor
function
Long-term MD = 0.80
(95% CI, 1.83
to 0.23)
Negative
The Executive Interview (EXIT-
25)
Self-reported
cognitive
function
Short-term MD = 1.60
(95% CI, 2.81
to 0.39)*
Positive
The Executive Interview (EXIT-
25)
Self-reported
cognitive
function
Long-term MD = 0.10
(95% CI, 1.35
to 1.15)
Negative
Complementary
alternative
medicine
Gingko biloba [34] Trail Making Test-A Orientation
and attention
Short-term,
medium-
term, long-
term
Data not
extractable
Inconclusive
Trail Making Test-B Orientation
and attention
Short-term,
medium-
term, long-
term
Data not
extractable
Inconclusive
Positive represents ‘favours intervention’ and Negative represents ‘does not favour intervention’. Measurement time points: short-term: less than
3 months; medium-term: 3–6 months; long-term: beyond 6 months. Abbreviations: MD, mean diﬀerence; CI, conﬁdence interval.
* p < 0.05.
# These subtest names do not appear in the original paper–they are derivative measures of a factor analysis.
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the level of diﬃculty and complexity increasing accord-
ing to a pre-determined algorithm. Compared to con-
trols, the intervention participants demonstrated
statistically signiﬁcant improvements in executive func-
tion as measured by the Delis–Kaplan measure of verbal
function and language skills (MD = 2.00 [95% CI, 0.78–
3.22]) and the Symbol Search measure of orientation
and attention (MD = 2.00 [95% CI, 0.16–3.84]).Dolbeault et al. [36] delivered a CBT-based stress
management intervention in which cognition, a second-
ary objective, was measured with the European Organi-
sation for Research and Treatment of Cancer
(EORTC)-Cognitive Functioning subscale. Results were
not statistically signiﬁcant for enhancements in cognitive
function. In another study, rather than traditional repet-
itive techniques of mental exercise in CBT that aim to
repair damaged neuro-circuitry to recover memory
Table 4
Non-pharmacologic interventions and outcomes (n = 7).
Categories Intervention Tool Domains examined Assessment
time point
Eﬀect size Conclusion
Cognitive
training
Computerised
cognitive training [39]
Wisconsin card sorting test Executive function and motor function Short-term MD = 3.00 (95% CI, 1.49 to 7.49) Negative
Delis–kaplan (letter ﬂuency) Verbal function and language skills Short-term MD = 2.00 (95% CI, 0.78 to 3.22)* Positive
Digit span Orientation and attention Short-term MD = 0.90 (95% CI, 3.17 to 1.17) Negative
Symbol search Orientation and attention Short-term MD = 2.00 (95% CI, 0.16 to 3.84)* Positive
Hopkins verbal learning test-revised
(HVLT-R)
Memory Short-term MD = 1.00 (95% CI, 5.95 to 3.95) Negative
BRIEF GEC Self-reported cognitive function Short-term MD = 2.00 (95% CI, 10.37 to
6.37)
Negative
BRIEF GEC (plan and organise) Self-reported cognitive function Short-term MD = 5.00 (95% CI, 13.30 to
3.30)
Negative
BRIEF GEC (task monitor) Self-reported cognitive function Short-term MD = 4.00 (95% CI, 10.75 to
2.75)
Negative
Cognitive-
behavioural therapy
[38]
Trail Making Test-B Orientation and attention Short-term MD = 3.22 (95% CI, 7.9 to 14.34) Negative
Colour word trail (D-KEFS subset) Executive function and motor function Short-term MD = 0.73 (95% CI, 6.44 to 4.98) Negative
Colour word switching trail (D-KEFS
subset)
Executive function and motor function Short-term MD = 0.53 (95% CI, 6.81 to 7.87) Negative
Digit symbol-coding (subtest of wechsler
adult intelligence scale)
Orientation and attention Short-term MD = 1.09 (95% CI, 0.75 to 2.93) Negative
California verbal learning test (CVLT) ii Memory Short-term MD = 4.26 (95% CI, 2.32 to 10.84) Negative
MASQ scores Self-reported cognitive function Short-term MD = 4.02 (95% CI, 8.83 to 16.87) Negative
Memory training [46] FACT-Cog Self-reported cognitive function Short-term MD = 9.85 (95% CI, 1.67–18.03)* Positive
Composite score: rey auditory verbal
learning test (AVLT) (sum recall, short
delay and recognition score and
rivermead behavioral paragraph recall
test (immediate recall score)
Memory Short-term MD = 0.31 (95% CI 0.04–0.58)* Positive
Composite score: rey auditory verbal
learning test (AVLT) (long term delay
score) and rivermead behavioural
paragraph recall test (long term delay
score)
Memory Short-term MD = 0.46 (95% CI, 0.120.80)* Positive
Speed of processing
training [46]
FACT-Cog Self-reported cognitive function Short-term MD = 6.66 (95% CI, 1.43 to 14.75) Negative
Composite score: rey auditory verbal
learning test (AVLT) (sum recall, short
delay and recognition score and
rivermead behavioral paragraph recall
test (immediate recall score)
Memory Short-term MD = 0.43 (95% CI, 0.160.70)* Positive
Composite score: rey auditory verbal
learning test (AVLT) (long term delay
score) and rivermead behavioral
paragraph recall test (long term delay
score)
Memory Short-term MD = 0.47 (95% CI, 0.13–0.81)* Positive
(continued on next page)
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Table 4 (continued )
Categories Intervention Tool Domains examined Assessment
time point
Eﬀect size Conclusion
Psycho-education
[36]
EORTC-CF Self-reported cognitive function Short-term MD = 0.16 (95% CI, 0.38 to 0.06) Negative
Tibetan sound [44] Rey auditory verbal learning test (AVLT) Memory Short-term Data not extractable Inconclusive
Digit span Orientation and attention Short-term MD = 0.43 (95% CI, 0.17 to 1.03) Negative
Digit symbol-coding (subtest of wechsler
adult intelligence scale)
Orientation and attention Short-term MD = 0.46 (95% CI, 0.14 to 1.06) Negative
Controlled oral word association test Verbal function and language skills Short-term MD = 0.00 (95% CI, 0.66 to 0.66) Negative
FACT-Cog (impairment) Self-reported cognitive function Short-term MD = 3.70 (95% CI, 8.20 to 15.60) Negative
FACT-Cog (ability) Self-reported cognitive function Short-term MD = 1.40 (95% CI, 3.06 to 5.86) Negative
FACT-Cog (other comment) Self-reported cognitive function Short-term MD = 0.40 (95% CI, 1.57 to 2.37) Negative
FACT-Cog (impact) Self-reported cognitive function Short-term MD = 0.10 (95% CI, 4.28 to 4.48) Negative
Exercise Speed-feedback
therapy with a bicycle
ergometer [43]
Frontal assessment battery Executive function and motor function Short-term MD = 1.66 (95% CI, 0.84–2.48)* Positive
Yoga [35] Symptoms of stress inventory (SOSI)
cognition subscale
Self-reported cognitive function Short-term MD = 1.67 (95% CI, 3.66 to 0.32) Negative
Proﬁle of moods scale (POMS)
concentration subscale
Self-reported cognitive function Short-term MD = 2.50 (95% CI, 4.56 to
0.44)*
Positive
Positive represents ‘favours intervention’ and Negative represents ‘does not favour intervention’. Abbreviations: BRIEF GEC: Behaviour Rating Inventory of Executive Function Global Executive
Composite; EORTC-CF: European Organisation for Research and Treatment of Cancer-Cognitive functioning subscale; FACT-Cog: Functional Assessment of Cancer Therapy-Cognitive Function;
GEC: Global Executive Composite; MASQ: Multiple Abilities Self-Report Questionnaire; CI: conﬁdence interval; MD: mean diﬀerence. Measurement time point: short-term: less than 3 months.
* p < 0.05.
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tive processing and new behaviour that compensated for
chronic memory dysfunction. This intervention entailed
the participants monitoring their cognitive failures and
learning new processes to succeed in daily activities in
which memory was required. The participants under-
took twice weekly face-to-face sessions of 30–50 min
each, with reinforcing phone contacts between each
visit. Diﬀerences in all outcome measures between inter-
vention and control were not signiﬁcant.
Milbury et al. [44] delivered a Tibetan sound medita-
tion intervention, based on the premise that the focused
concentration of such meditation, coupled with aware-
ness, stress reduction and relaxation techniques would
improve objective cognitive performance. Each partici-
pant undertook 60-min meditation classes twice weekly
for 6 weeks. Compared to controls, the intervention
did not result in signiﬁcant diﬀerences in objectively or
subjectively measured cognitive function.3.2.2. Physical activity
One physical activity intervention [43] comprised
speed feedback therapy with a bicycle ergometer con-
nected to a computer. Participants pedaled the bike to
match the target arbitrarily displayed on the computer
screen, which appeared as a pathway. The participants
were instructed to pedal while visually tracking the path,
and they undertook one pedaling session per week for
4 weeks. The exercise load was pre-set, with the partici-
pants pedaling for 5 min each session. Compared to con-
trols, the intervention participants had improved
executive function and motor function as measured by
the Frontal Assessment Battery (MD = 2.50 [95%
CI, 4.56 to 0.44]).
Culos-Reed et al. [35] delivered a programme of mod-
iﬁed hatha yoga, which focused on relaxation and
awareness of breathing, body sensations and thoughts,
to enhance post-treatment quality of life. Participants
progressively built ﬂexibility, strength and balance while
maintaining awareness and relaxation. A reduction of
cognitive disorganisation (as measured by the Proﬁle
of Mood State [POMS] Concentration subscale) was
demonstrated in the intervention group compared to
the control immediately on conclusion of the pro-
gramme (MD = 2.50 [95% CI, 4.56 to 0.44]).4. Discussion
Current evidence does not favour the pharmacologic
management of cognitive alteration associated with
breast cancer treatment. The inherent variability of the
psychology-derived cognitive training interventions
makes it diﬃcult to determine their role in practice.
Some forms of cognitive training, particularly those that
focus on quality of life enhancements, hold potential.
For example, one study demonstrated a clinicallyimportant (i.e. subjectively reported) and statistically
signiﬁcant beneﬁt in cognition-related quality of life
[46]. Physical activity interventions also appear promis-
ing; however, methodological challenges in these studies
preclude any concrete recommendations for practice.
Psychostimulants eﬀectively manage cognitive issues
related to attention deﬁcit hyperactivity disorder and
neurodegenerative diseases. The studies included in this
review hypothesised that these agents are as eﬀective in
treating chemotherapy-associated cognitive alterations.
These drugs include methylphenidate and d-MPH,
which are sympathomimetic amines that modulate neu-
rotransmitters in the brain. They are short-acting and
were prescribed for a limited time during chemotherapy
in these studies; therefore, the long-term beneﬁts were
not assessed. The long-term beneﬁts of psychostimulants
have not been established [47], which suggests limited
clinical beneﬁts for individuals previously treated for
breast cancer [37,41,42]. Similar to the sympathomimet-
ics, modaﬁnil improves wakefulness by acting on speciﬁc
pathways in the brain that regulate sleep-wake patterns,
without increasing the risk of the extrapyramidal side-
eﬀects that are commonly observed with sympathomi-
metics. Although patients receiving this treatment
achieved a level of improvement in the open-label phase
of the study [40], this review did not detect any subse-
quent beneﬁt in the randomised phase. In summary,
the role of these agents is limited. In addition to conven-
tional medications, herbal supplements such as Ginkgo
biloba were also investigated as potential cognitive
enhancers [34]. The literature indicates that Ginkgo
biloba may improve cognitive function in patients with
mild or moderate Alzheimer’s disease or dementia
[48,49]. However, no beneﬁts were observed in the study
by Barton et al. [34]. The authors proposed that the
mechanisms underpinning chemotherapy-induced cog-
nitive changes are diﬀerent from those associated with
dementia [34].
In terms of non-pharmacologic interventions, cogni-
tive training is useful in a range of conditions such as
traumatic brain injury, which, like chemotherapy-asso-
ciated dysfunction, demonstrate more subtle cognitive
impairment [39]. Physical activity and cognitive training
techniques involve repeated skills and awareness prac-
tice, adaptive diﬃculty levels and an engaging and
rewarding environment. It is possible that these aspects
of the interventions might not necessarily target cogni-
tive function. However, they could yield positive beneﬁts
in cognitive organisation due to overall enhancement of
self-reported quality of life [38]. Given that quality of
life was a primary or secondary end-point in six of the
seven non-pharmacologic studies in this review, and that
improvements in the participants’ quality of life were
integral to many of these interventions, this assumption
is worthy of empirical investigation.
A number of other interventions not included in this
review also warrant further exploration. For example,
448 R.J. Chan et al. / European Journal of Cancer 51 (2015) 437–450the eﬀectiveness of cholinesterase inhibitors (such as
donepezil) and antioxidants (such as vitamin E) were
investigated in the prevention of cognitive decline in
patients with small cell lung cancer [50]. Unfortunately,
poor patient accrual led to the early closure of the study.
The results of trials of granulocyte macrophage-colony
stimulating factor [50], memantine [19] and medical
qigong [29] are also promising, and further evaluations
are required.
A number of methodological limitations featured in
the included studies. First, there was at least one ROB
in all of the studies. Second, the treatment characteris-
tics of the participants were variable (e.g. they were at
diﬀerent stages of the disease, or received diﬀerent treat-
ment regimens). Third, the studies did not explain
whether the participants were primed for cognitive
impairment, with the entry criteria of many studies stip-
ulating self-reported cognitive function. Fourth, the par-
ticipants could not be blinded to the intervention in the
non-pharmacologic studies. Fifth, many interventions
required an intense commitment and repeat visits from
participants, yet their sustainability over time is hard
to determine, particularly where losses to follow-up were
not documented [34–37,44,45]. Eleven studies did not
evaluate the sustainability of eﬀects beyond 3 months,
by which time most of the interventions had ceased.
Sixth, the majority of studies involved less than 50 par-
ticipants per arm, although we recognize that many were
pilot and feasibility investigations, which are integral
components of high-quality research programmes. We
also recognize that there may be a potential risk of pub-
lication bias with studies reporting negative results
remaining unpublished.
Seventh, some of the included studies did not include
cognitive function as a primary end-point. Trials are
often not powered to detect diﬀerences in secondary out-
comes. However, we included these studies due to the
potential for meta-analysis. Finally, the majority of the
studies were undertaken in North America. Given that
a patient’s symptom experience is often culturally spe-
ciﬁc [51], the generalisability of these results to other
sociocultural contexts is uncertain.
The problems reﬂected in the range of methodologies
and diﬀerent cognitive outcomes reported in these stud-
ies could be addressed through the harmonisation of
intervention studies. The International Cognition and
Cancer Task Force [52] provide some useful guidance
in this respect. They recommend for observational stud-
ies that pre-treatment cognitive function is assessed, that
intervention and control groups are standardised in
terms of regimen and type of cancer, and that neuropsy-
chological outcome measures are harmonised. These
principles are equally germane to intervention studies.
This review suggests that in any intervention study in
this ﬁeld, the patient cohort requires careful consider-
ation in terms of the stage of cancer and time sincediagnosis. Studies could incorporate a screen for expec-
tancy eﬀects prior to randomisation that are controlled
for during data analysis. Expectancies and stereotypes
including those associated with diagnoses are known
to inﬂuence cognitive proﬁles [53]. Screening should also
assess premorbid cognitive function if possible [54]. Sub-
jective and objective measurements appear to be equally
important in detecting eﬀects. Self-reported measures
detect outcomes that are clinically signiﬁcant to patients,
whereas objective neuropsychological tests remain the
gold standard [52]. Utilisation of validated tools would
also be essential for future interventional studies.
Future studies would beneﬁt from the addition of an
attention control arm to address the bias inherent in the
inability to blind in non-pharmacologic studies [55,56].
The potential uptake of the intervention should also
be carefully considered. Aside from feasibility studies
to determine this, interventions need to be accessible
and easy for patients to undertake. Technology-
enhanced interventions have promise, particularly mul-
timodal programmes that combine physical activity
and cognitive training.
In summary, the burden associated with this com-
monly reported problem in the breast cancer community
is signiﬁcant. The science to address this problem, how-
ever, is imprecise. Well-designed clinical studies are
clearly warranted to enhance the quality of life and func-
tion of this growing population.
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